Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for ...

Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple ...

MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity” or "the Company”), a biotechnology company dedicated to developing ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA).

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has announced the completion of its last patient visit in the ATH434-202 ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H ...

Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open ...

New research suggests that people who take significantly longer to start the dream phase of sleep may be showing an early ...